Hailey Borg
Healthcare: Biotech and Pharma Innovation
Expected Outperformers: Moderna, Vertex Pharmaceuticals, BioNTech
Why: Expanding mRNA applications in cancer and personalised medicine. Vertex is a leader in cystic fibrosis treatments with a promising gene-editing pipeline.
Wildcard: CRISPR Therapeutics
Why: Gene therapy approvals could catalyse exponential growth for this early-stage biotech company.
Financial Services: The DeFi and Payment Revolution
Expected Outperformers: Visa, Mastercard, PayPal
Why: Expansion into digital currencies and a robust consumer spending recovery.
Wildcard: Block (formerly Square)
Why: Its blockchain payment solutions and small business services offer strong growth potential.
Industrial Automation and Robotics
Expected Outperformers: ABB, Fanuc Corporation, Rockwell Automation
Why: Labour shortages and rising costs will drive demand for automation in manufacturing and logistics.
Wildcard: UiPath
Why: Its market position in robotic process automation (RPA) for enterprise clients ensures significant growth opportunities.
By identifying these outperformers and risks, investors can better navigate 2025’s complexities and capitalise on emerging opportunities. Let me know if you’d like a deep dive into any specific company or sector!
You Might Also Like
Latest Article
Trade Gap Halves In December As Imports Fall And Exports Rise
Malta’s trade deficit narrowed significantly in December, driven by a sharp drop in imports alongside an increase in exports, according to provisional data published by the National Statistics Office. The figures show that the trade gap stood at €191.7 million in December, compared to a deficit of €368.5 million in the same month of 2024. … Continued
|
9 February 2026
Written by MeetInc.
A Conversation On Compliance: ARQ GROUP On How Regulation, Risk And Technology Are Reshaping The Rulebook
|
5 February 2026
Written by Hailey Borg
HSBC Malta Launches 2026 Campaign With Wealth, Lending And Insurance Offers
|
4 February 2026
Written by MeetInc.
